Press release article from our research archive:

Ritalin (R) LA, a New Once-Daily Treatment for ADHD, Receives FDA Approvable Letter.

EAST HANOVER, N.J., and WARREN, N.J., Oct. 2 /PRNewswire/ --

Novartis Pharmaceuticals Corporation and Celgene Corporation announced today that they received an approvable letter from the U.S. Food and Drug Administration (FDA) for Ritalin (R) LA (methylphenidate HCl extended-release capsules) for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). Ritalin LA is a new, once-daily formulation of Ritalin (R) (methylphenidate HCl), which eliminates the need for a mid-day dose during school.

An approvable letter usually represents the final step before a product receives FDA clearance for marketing in the United States. Ritalin LA is part of a broad ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!